Literature DB >> 6428554

Hepatitis B virus infection in thalassaemia major treated in London and Athens.

G Mieli-Vergani, D Vergani, Y White, A P Mowat, B Wonke, C J Kennedy, A Karameau, D Politis, M Laulicht, A V Hoffbrand.   

Abstract

Entities:  

Mesh：

Year:  1984        PMID： 6428554      PMCID： PMC1441888          DOI： 10.1136/bmj.288.6433.1804

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Antibody to hepatitis B core antigen. A sensitive indicator of hepatitis B virus replication.

Authors:  J H Hoofnagle; R J Gerety; L Y Ni; L F Barker
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

2.  Viral hepatitis markers in blood donors with history of jaundice.

Authors:  R S Tedder; C H Cameron; J A Barbara; D Howell
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

3.  Role of chronic hepatitis in development of thalassaemic liver disease.

Authors:  G Masera; G Jean; G Gazzola; M Novakova
Journal:  Arch Dis Child       Date:  1976-09       Impact factor: 3.791

4.  Prevalence of hepatitis A and B infections in multiply transfused thalassaemic patients.

Authors:  G Papaevangelou; G Frösner; J Economidou; S Parcha; A Roumeliotou
Journal:  Br Med J       Date:  1978-03-18
  4 in total
  2 in total

1.  Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease.

Authors:  Q Mok; G Underhill; B Wonke; M Aldouri; M Kelsey; D Jefferies
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

2.  Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major.

Authors:  I al-Fawaz; S Ramia
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.